knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 23:47:23 - browse：21

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： States should stop sabotaging methadone treatment reform

WSS

Cheap, fast test for Zika and dengue could cost just $1

The system is set up to fail children with medical complexity

Washington mulls new rules to avert another Change Healthcare

Steward Health Care has deal to sell doctor network to UnitedHealth

STAT Virtual Event: ASCO Recap, Live!

STAT Virtual Event: ASCO Recap, Live!

hotspot

knowledge

leisure time

In Memoriam: Notable people who died in 2023

Curing rare childhood diseases will falter unless Congress steps up

Heart attack and stroke risk calculators need revising

Steward Health Care has deal to sell doctor network to UnitedHealth

BioMarin wins approval for gene therapy to treat hemophilia A

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Bright Health sells Medicare Advantage business to Molina

Teladoc has a new CEO, but challenges remain the same

Medical records are filled with copy

Statins may not be needed by millions of people, study suggests

focus

Cigna wins case to block Amy Bricker's move to CVS

States should stop sabotaging methadone treatment reform

Will generative AI in health care meet the fate of IBM's Dr. Watson?

States should stop sabotaging methadone treatment reform

Curing rare childhood diseases will falter unless Congress steps up

Coercive sterilizations revealed by STAT prompt outrage

hotspot

focus

focus

leisure time